This session provided an overview of the predictive biomarkers in pancreas and biliary cancer, while emphasizing the challenges that labs are facing today, and discuss new therapeutic strategies.
Aiming for targets in pancreas and biliary cancer - new possibilities to hit?
Access the recording now.
Sign up to DXRX to access the recording!
- Diaceutics - Welcome & introduction to Diaceutics
- Dr. Lena Julia Häberle - Predictive biomarkers in biliary cancer
- Dr. Lena Julia Häberle - Predictive biomarkers in pancreatic cancer
- Dr. Simon Labuhn - New therapeutic strategies in pancreatobiliary cancer
- All participants - Q&A
Speaker name: Dr. med. Lena Julia Häberle
Lena Häberle is a certified pathologist since 2022 at the Institute of Pathology, University Hospital and Heinrich Heine University where she also did her training under the supervision of Prof. Irene Esposito.Her research interest has been focused on pancreas cancer, histopathology as well as immunohistochemistry.In 2020 she was involved in the preparation and development of the Consensus Guidelines for Chronic Pancreatitis.
Speaker name: Dr. med. Simon Labuh
Simon Labuhn is a specialist in internal medicine and gastroenterology. He is interested in the role of innovative biomarker candidates in gastrointestinal cancer and other GI diseases and in the evaluation and implantation of clinical decision-making tools/algorithms in real-world patient cohorts.Together with Dr. Lena Häberle he is participating in the Molecular Tumour Boards of the Heinrich Heine University Düsseldorf.